Semin Respir Crit Care Med 2009; 30(5): 547-558
DOI: 10.1055/s-0029-1238913
© Thieme Medical Publishers

Improving Care at Cystic Fibrosis Centers through Quality Improvement

Nathan C. Kraynack1 , John T. McBride1
  • 1Division of Pediatric Pulmonology, Akron Children's Hospital, Akron, Ohio
Further Information

Publication History

Publication Date:
16 September 2009 (online)

ABSTRACT

Quality improvement (QI) using a clinical microsystems approach provides cystic fibrosis (CF) centers the opportunity to make a significant positive impact on the health of their patients. The availability of center-specific outcomes data and the support of the Cystic Fibrosis Foundation are important advantages for these quality improvement efforts. This article illustrates how the clinical microsystems methodology can improve care delivery and outcomes by describing the gradual application of quality improvement principles over the past 5 years by the CF team at the Lewis Walker Cystic Fibrosis Center at Akron Children's Hospital in Akron, Ohio. Using the example of a project to improve the pulmonary function of the pediatric patients at our center as a framework, we describe the QI process from the initial team-building phase, through the assessment of care processes, standardization of care, and developing a culture of continuous improvement. We outline how enthusiastic commitment from physician leadership, clinical managers and central administration, the availability of coaches, and an appreciation of the importance of measurement, patient involvement, communication, and standardization are critical components for successful process improvement.

REFERENCES

  • 1 Marshall B C. Overview of CFF strategic QI initiative. Presented at: Cystic Fibrosis Foundation's Learning and Leadership Collaborative: Accelerating the Rate of Improvement in CF Care June 28, 2004 Baltimore, MD;
  • 2 Nelson E C, Batalden P B, Huber T P et al.. Microsystems in health care, I: Learning from high-performing front-line clinical units.  Jt Comm J Qual Improv. 2002;  28 472-493
  • 3 Cystic Fibrosis Foundation .PortCF Web portal. Available at: https://www.portcf.org/educationalmaterials.asp?folder=%2FResources%2FConsensus+%26+Guidelines Accessed March 15, 2009
  • 4 O’Connor G T, Quinton H B, Sabadosa K A, Hazle L, Marshall B C. An intervention to accelerate the rate of improvement in the Cystic Fibrosis Foundation Care Center Network.  JAMA. 2009;  , submitted for publication
  • 5 Cystic Fibrosis Foundation .Action Guide for Accelerating the Rate of Improvement in Cystic Fibrosis Care. Cystic Fibrosis Foundation, Clinical Microsystems 2006
  • 6 de Koning H, Verver J P, van den Heuvel J, Bisgaard S, Does R J. Lean six sigma in healthcare.  J Healthc Qual. 2006;  28 4-11
  • 7 Clinical Microsystems Website. Available at: http://dms.dartmouth.edu/cms/ Accessed March 1, 2009
  • 8 Kraynack N C, Olbrych T G, McBride J T. Variation in management of CF pulmonary exacerbations among providers at a single CF center based on clinical scenarios [abstract].  Pediatr Pulmonol Suppl. 2005;  28 303
  • 9 Kraynack N C, Falletta L M, McBride J T. Approach to treating exacerbations of CF lung disease as measured by clinical vignettes varies widely within and between CF centers [abstract].  Pediatr Pulmonol Suppl. 2008;  31 365
  • 10 Kraynack N C, Omlor G J, Ouellette D A, Singh C M. Implementation of a pulmonary exacerbation scoring system to uniformly identify pulmonary exacerbations in children 6–18 years of age [abstract].  Pediatr Pulmonol Suppl. 2005;  28 302-303
  • 11 Kraynack N C, Singh C M, Sheers T G, Bryson E A, McBride J T. Standardization of a pulmonary exacerbation score designed to uniformly identify pulmonary exacerbations in cystic fibrosis is associated with continued improvement in pulmonary function [abstract].  Pediatr Pulmonol Suppl. 2007;  42 372
  • 12 Rosenfeld M, Emerson J, Williams-Warren J et al.. Defining a pulmonary exacerbation in cystic fibrosis.  J Pediatr. 2001;  139 359-365
  • 13 Fuchs H J, Borowitz D S, Christiansen D H The Pulmozyme Study Group et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis.  N Engl J Med. 1994;  331 637-642
  • 14 Blumer J L, Saiman L, Konstan M W, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.  Chest. 2005;  128 2336-2346
  • 15 Rabin H R, Butler S M, Wohl M E Epidemiologic Study of Cystic Fibrosis et al. Pulmonary exacerbations in cystic fibrosis.  Pediatr Pulmonol. 2004;  37 400-406
  • 16 Dakin C, Henry R L, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis.  Pediatr Pulmonol. 2001;  31 436-442

Nathan C KraynackM.D. 

Division of Pediatric Pulmonology, Akron Children's Hospital

One Perkins Sq., Akron, OH 44308

Email: nkraynack@chmca.org

    >